Citations (90)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (22)
Vahideh Ahmadzadeh, Roghaye Tofigh, Safar Farajnia & Nasser Pouladi. (2016) The Central Role for Microenvironment in B-Cell Malignancies: Recent Insights into Synergistic Effects of its Therapeutic Targeting and Anti-CD20 Antibodies. International Reviews of Immunology 35:2, pages 136-155.
Read now
Read now
Kristen Ganjoo, Fangxin Hong, Sandra J. Horning, Randy D. Gascoyne, Yasodha Natkunam, Lode J. Swinnen, Thomas M. Habermann, Brad S. Kahl & Ranjana H. Advani. (2014) Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404). Leukemia & Lymphoma 55:4, pages 768-772.
Read now
Read now
Georgios S. Dimtsas, Eleni C. Georgiadi, Petros Karakitsos, Theodoros P. Vassilakopoulos, Irene Thymara, Penelope Korkolopoulou, Efstratios Patsouris, Christos Kittas & Ipatia A. Doussis-Anagnostopoulou. (2014) Prognostic significance of immunohistochemical expression of the angiogenic molecules vascular endothelial growth factor-A, vascular endothelial growth factor receptor-1 and vascular endothelial growth factor receptor-2 in patients with classical Hodgkin lymphoma. Leukemia & Lymphoma 55:3, pages 558-564.
Read now
Read now
Tadeusz Robak, Pawel Robak & Piotr Smolewski. (2012) The evaluation and optimal use of rituximab in lymphoid malignancies. Blood and Lymphatic Cancer: Targets and Therapy 2, pages 1-16.
Read now
Read now
Chadi Nabhan & Jayesh Mehta. (2012) Diffuse large B-cell lymphoma: is there a place for autologous hematopoietic stem cell transplant in first remission in the era of chemo-immunotherapy?. Leukemia & Lymphoma 53:10, pages 1859-1866.
Read now
Read now
Ranjana H. Advani, Fangxin Hong, Sandra J. Horning, Brad S. Kahl, Judith Manola, Lode J. Swinnen, Thomas M. Habermann & Kristen Ganjoo. (2012) Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial. Leukemia & Lymphoma 53:4, pages 718-720.
Read now
Read now
Stephen J. Demarest, Kandasamy Hariharan & Jianying Dong. (2011) Emerging antibody combinations in oncology. mAbs 3:4, pages 338-351.
Read now
Read now
Rajni Sinha, Nutan DeJoubner & Christopher Flowers. (2011) Novel agents for diffuse large B-cell lymphoma. Expert Opinion on Investigational Drugs 20:5, pages 669-680.
Read now
Read now
Mary J. Ninan, Punit D. Wadhwa & Pankaj Gupta. (2011) Prognostication of diffuse large B-cell lymphoma in the rituximab era. Leukemia & Lymphoma 52:3, pages 360-373.
Read now
Read now
Niels Murawski, Carsten Zwick & Michael Pfreundschuh. (2010) Unresolved issues in diffuse large B-cell lymphomas. Expert Review of Anticancer Therapy 10:3, pages 387-402.
Read now
Read now
Oliver Weigert, Michael Unterhalt, Wolfgang Hiddemann & Martin Dreyling. (2009) Mantle cell lymphoma: state-of-the-art management and future perspective. Leukemia & Lymphoma 50:12, pages 1937-1970.
Read now
Read now
Javier Briones. (2009) Emerging therapies for B-cell non-Hodgkin lymphoma. Expert Review of Anticancer Therapy 9:9, pages 1305-1316.
Read now
Read now
Anne Sonet & André Bosly. (2009) Rituximab and chemotherapy in diffuse large B-cell lymphoma. Expert Review of Anticancer Therapy 9:6, pages 719-726.
Read now
Read now
Jia Ruan & John P. Leonard. (2009) Targeting angiogenesis: a novel, rational therapeutic approach for non-Hodgkin lymphoma. Leukemia & Lymphoma 50:5, pages 679-681.
Read now
Read now
Claudia Stolz & Martin Schuler. (2009) Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention. Leukemia & Lymphoma 50:6, pages 873-885.
Read now
Read now
Alison T. Stopeck, Joseph M. Unger, Lisa M. Rimsza, William T. Bellamy, Maria Iannone, Daniel O. Persky, Michael Leblanc, Richard I. Fisher & Thomas P. Miller. (2009) A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108. Leukemia & Lymphoma 50:5, pages 728-735.
Read now
Read now
Maricer P Escalón & Izidore S Lossos. (2008) Pharmacotherapy of large B-cell lymphoma. Expert Opinion on Pharmacotherapy 9:13, pages 2247-2258.
Read now
Read now
Alexandra Giatromanolaki, Michael I. Koukourakis, Francesco Pezzella, Efthimios Sivridis, Helen Turley, Adrian L. Harris & Kevin C. Gatter. (2008) Lactate dehydrogenase 5 expression in non-Hodgkin B-cell lymphomas is associated with hypoxia regulated proteins. Leukemia & Lymphoma 49:11, pages 2181-2186.
Read now
Read now
Aaron Polliack, Koen van Besien & John F. Seymour. (2008) 2007: The year in review for Leukemia and Lymphoma. Leukemia & Lymphoma 49:1, pages 1-3.
Read now
Read now
Ghada Kchour, Mahdi Tarhini, Nourieh Sharifi, Reza Farid, Ali Reza Khooei, Abbas Shirdel, Jalil Tavakkol Afshari, Ali Sadeghian, Zaher Otrock, Olivier Hermine, Marwan El-Sabban & Ali Bazarbachi. (2008) Increased microvessel density in involved organs from patients with HTLV-I associated adult T cell leukemia lymphoma. Leukemia & Lymphoma 49:2, pages 265-270.
Read now
Read now
Kristen Ganjoo. (2007) Antiangiogenesis: A new approach to the treatment of lymphoma. Leukemia & Lymphoma 48:3, pages 454-455.
Read now
Read now
C. Portlock. (2006) Anti-angiogenesis and diffuse large B-cell lymphoma: a new treatment opportunity?. Leukemia & Lymphoma 47:6, pages 961-962.
Read now
Read now
Articles from other publishers (68)
Domenico Ribatti, Roberto Tamma, Tiziana Annese, Antonio d’Amati, Giuseppe Ingravallo & Giorgina Specchia. (2023) Vascular Growth in Lymphomas: Angiogenesis and Alternative Ways. Cancers 15:12, pages 3262.
Crossref
Crossref
Maike Stegemann, Sophy Denker & Clemens A. Schmitt. (2022) DLBCL 1L—What to Expect beyond R-CHOP?. Cancers 14:6, pages 1453.
Crossref
Crossref
Lutz Menzel, Uta E. Höpken & Armin Rehm. (2020) Angiogenesis in Lymph Nodes Is a Critical Regulator of Immune Response and Lymphoma Growth. Frontiers in Immunology 11.
Crossref
Crossref
Marleen Gloger, Lutz Menzel, Michael Grau, Anne-Clemence Vion, Ioannis Anagnostopoulos, Myroslav Zapukhlyak, Kerstin Gerlach, Thomas Kammertöns, Thomas Hehlgans, Maria Zschummel, Georg Lenz, Holger Gerhardt, Uta E. Höpken & Armin Rehm. (2020) Lymphoma Angiogenesis Is Orchestrated by Noncanonical Signaling Pathways. Cancer Research 80:6, pages 1316-1329.
Crossref
Crossref
VaibhavBansidhar Patil, SnehalBalvant Lunge & BhavanaRavindra Doshi. (2020) Cardiac side effect of rituximab. Indian Journal of Drugs in Dermatology 6:1, pages 49.
Crossref
Crossref
Kinjal Sanghavi, Jason Zhang, Xiaochen Zhao, Yan Feng, Paul Statkevich, Jennifer Sheng, Amit Roy & Heather E. Vezina. (2019) Population Pharmacokinetics of Ipilimumab in Combination With Nivolumab in Patients With Advanced Solid Tumors. CPT: Pharmacometrics & Systems Pharmacology 9:1, pages 29-39.
Crossref
Crossref
Lauren Lupino, Tracey Perry, Sandra Margielewska, Robert Hollows, Maha Ibrahim, Matthew Care, Jeremy Allegood, Reuben Tooze, Roger Sabbadini, Gary Reynolds, Roy Bicknell, Zbigniew Rudzki, Ye Lin Hock, Ulises Zanetto, Wenbin Wei, William Simmons, Sarah Spiegel, Ciaran B. J. Woodman, Martin Rowe, Katerina Vrzalikova & Paul G. Murray. (2019) Sphingosine-1-phosphate signalling drives an angiogenic transcriptional programme in diffuse large B cell lymphoma. Leukemia 33:12, pages 2884-2897.
Crossref
Crossref
Li Wang, Shaoyong Peng, Weipeng Sun & Xiaoxia Liu. (2019)
Retracted:
Bevacizumab synergises with the BCL 2 inhibitor venetoclax to effectively treat B‐cell non‐Hodgkin's lymphoma
. European Journal of Haematology 103:3, pages 234-246.
Crossref
Crossref
Ran Liu, Zhi Chen, Shujun Wang, Gang Zhao, Yan Gu, Qi Han & Baoan Chen. (2019) Screening of key genes associated with R‑CHOP immunochemotherapy and construction of a prognostic risk model in diffuse large B‑cell lymphoma. Molecular Medicine Reports.
Crossref
Crossref
Renée L Mulder, Dorine Bresters, Malon Van den Hof, Bart GP Koot, Sharon M Castellino, Yoon Kong K Loke, Piet N Post, Aleida Postma, László P Szőnyi, Gill A Levitt, Edit Bardi, Roderick Skinner & Elvira C van Dalen. (2019) Hepatic late adverse effects after antineoplastic treatment for childhood cancer. Cochrane Database of Systematic Reviews.
Crossref
Crossref
José M. Serra López-Matencio, Alberto Morell Baladrón & Santos Castañeda. (2018) Interacciones farmacológicas de los anticuerpos monoclonales. Medicina Clínica 151:4, pages 148-155.
Crossref
Crossref
José M. Serra López-Matencio, Alberto Morell Baladrón & Santos Castañeda. (2018) Pharmacological interactions of monoclonal antibodies. Medicina Clínica (English Edition) 151:4, pages 148-155.
Crossref
Crossref
G. Iacoboni, E. Zucca, M. Ghielmini & A. Stathis. (2018) Methodology of clinical trials evaluating the incorporation of new drugs in the first-line treatment of patients with diffuse large B-cell lymphoma (DLBCL): a critical review. Annals of Oncology 29:5, pages 1120-1129.
Crossref
Crossref
Wisit Cheungpasitporn, Stephen L. Kopecky, Ulrich Specks, Kharmen Bharucha & Fernando C. Fervenza. (2016) Non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy. Journal of Renal Injury Prevention 6:1, pages 18-25.
Crossref
Crossref
Nicola Ferri, Stefano Bellosta, Ludovico Baldessin, Donatella Boccia, Giorgi Racagni & Alberto Corsini. (2016) Pharmacokinetics interactions of monoclonal antibodies. Pharmacological Research 111, pages 592-599.
Crossref
Crossref
Katherine L. Gill, Krishna K. Machavaram, Rachel H. Rose & Manoranjenni Chetty. (2016) Potential Sources of Inter-Subject Variability in Monoclonal Antibody Pharmacokinetics. Clinical Pharmacokinetics 55:7, pages 789-805.
Crossref
Crossref
Shuyun Rao, Kathy Q. Cai, Jason E. Stadanlick, Noa Greenberg-Kushnir, Nehal Solanki-Patel, Sang-Yun Lee, Shawn P. Fahl, Joseph R. Testa & David L. Wiest. (2016) Ribosomal Protein Rpl22 Controls the Dissemination of T-cell Lymphoma. Cancer Research 76:11, pages 3387-3396.
Crossref
Crossref
Linda M. Henricks, Jan H.M. Schellens, Alwin D.R. Huitema & Jos H. Beijnen. (2015) The use of combinations of monoclonal antibodies in clinical oncology. Cancer Treatment Reviews 41:10, pages 859-867.
Crossref
Crossref
Magdalena Witkowska & Piotr Smolewski. (2015) Emerging immunotherapy and strategies directly targeting B cells for the treatment of diffuse large B-cell lymphoma. Immunotherapy 7:1, pages 37-46.
Crossref
Crossref
Jing Yang, Wenlu Li, Xin He, Guofei Zhang, Lan Yue & Ying Chai. (2015) VEGF Overexpression Is a Valuable Prognostic Factor for Non-Hodgkin’s Lymphoma Evidence from a Systemic Meta-Analysis. Disease Markers 2015, pages 1-9.
Crossref
Crossref
Zhiying Fu, Jun Zhu, Wen Zheng, Weiping Liu, Zhitao Ying, Yan Xie, Xiaopei Wang, Ningjing Lin, Meifeng Tu, Lingyan Ping, Lijuan Deng, Chen Zhang, Ning Ding & Yuqin Song. (2014) Safety and efficacy of bevacizumab combined with R-CHOP regimen in seven Chinese patients with untreated diffuse large B-cell lymphoma. Cancer Cell International 14:1.
Crossref
Crossref
Monika Podhorecka, Justyna Markowicz, Agnieszka Szymczyk & Johannes Pawlowski. (2014) Target Therapy in Hematological Malignances: New Monoclonal Antibodies. International Scholarly Research Notices 2014, pages 1-16.
Crossref
Crossref
Jia Ruan, Stephanie A. Gregory, Paul Christos, Peter Martin, Richard R. Furman, Morton Coleman & John P. Leonard. (2014) Long-Term Follow-Up of R-CHOP With Bevacizumab as Initial Therapy for Mantle Cell Lymphoma: Clinical and Correlative Results. Clinical Lymphoma Myeloma and Leukemia 14:2, pages 107-113.
Crossref
Crossref
Jean W Lee. (2013) ADME of monoclonal antibody biotherapeutics: knowledge gaps and emerging tools. Bioanalysis 5:16, pages 2003-2014.
Crossref
Crossref
Jia Ruan, Min Luo, Chunjie Wang, Lei Fan, Shao Ning Yang, Mariano Cardenas, Huimin Geng, John P. Leonard, Ari Melnick, Leandro Cerchietti & Katherine A. Hajjar. (2013) Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes. Blood 121:26, pages 5192-5202.
Crossref
Crossref
Ewa Lech-Maranda, Jacques Bienvenu, Florence Broussais-Guillaumot, Anne-Sophie Michallet, Krzysztof Warzocha, Przemysław Biliński, Peter Boyle, Bertrand Coiffier & Gilles Salles. (2013) Pretreatment Levels of Vascular Endothelial Growth Factor in Plasma Predict a Complete Remission Rate and Time to Relapse or Progression in Patients with Diffuse Large B-Cell Lymphoma. Archivum Immunologiae et Therapiae Experimentalis 61:2, pages 165-174.
Crossref
Crossref
Domenico Ribatti, Beatrice Nico, Girolamo Ranieri, Giorgina Specchia & Angelo Vacca. (2013) The Role of Angiogenesis in Human Non-Hodgkin Lymphomas. Neoplasia 15:3, pages 231-238.
Crossref
Crossref
Fabrice Jardin & Hervé Tilly. 2013. Lymphoma. Lymphoma
177
202
.
Semra Paydas. (2011) Strong cross-talk between angiogenesis and EBV: do we need different treatment approaches in lymphoma cases with EBV and/or high angiogenic capacity. Medical Oncology 29:3, pages 2159-2165.
Crossref
Crossref
Lin Xie, Li-Da Shen, Chen Qing, Zuo-Zhang Yang, Ke Li, Yang Li & Ji-Lan Yang. (2011) Correlational study of vascular endothelial growth factor expression and microvessel density in primary malignant gastric lymphoma. Medical Oncology 29:3, pages 1711-1715.
Crossref
Crossref
Alison T. StopeckJoseph M. UngerLisa M. RimszaMichael LeBlancBrent FarnsworthMaria IannoneMartha J. Glenn, Richard I. Fisher & Thomas P. Miller. (2012) A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515. Blood 120:6, pages 1210-1217.
Crossref
Crossref
B. Wolfesberger, Z. Tonar, A. Fuchs-Baumgartinger, I. Walter, M. Skalicky, K. Witter, J.G. Thalhammer, M. Pagitz & M. Kleiter. (2012) Angiogenic markers in canine lymphoma tissues do not predict survival times in chemotherapy treated dogs. Research in Veterinary Science 92:3, pages 444-450.
Crossref
Crossref
F Mori, T Ishida, A Ito, F Sato, A Masaki, H Takino, M Ri, S Kusumoto, H Komatsu, R Ueda, H Inagaki & S Iida. (2012) Potent antitumor effects of bevacizumab in a microenvironment-dependent human lymphoma mouse model. Blood Cancer Journal 2:4, pages e67-e67.
Crossref
Crossref
Deepti Aggarwal, Gunjan Srivastava, Ruchika Gupta, Leela Pant, Gopal Krishan & Sompal Singh. (2012) Angiogenesis in Non-Hodgkin's Lymphoma: An Intercategory Comparison of Microvessel Density. ISRN Hematology 2012, pages 1-5.
Crossref
Crossref
Min Kyoung Kim, Cheolwon Suh, Hyun Sook Chi, Hee Soon Cho, Young Kyung Bae, Kyung Hee Lee, Gyeong‐Won Lee, In‐Suk Kim, Hyeon‐Seok Eom, Sun‐Young Kong, Sung Hwa Bae, Hun Mo Ryoo, Im‐Hee Shin, Yeung‐Chul Mun, Hwasoon Chung & Myung Soo Hyun. (2012)
VEGFA
and
VEGFR2
genetic polymorphisms and survival in patients with diffuse large B cell lymphoma
. Cancer Science 103:3, pages 497-503.
Crossref
Crossref
Lale Kostakoglu. (2012) Novel PET Radiotracers for Potential Use in Management of Lymphoma. PET Clinics 7:1, pages 83-117.
Crossref
Crossref
Wosztyl Anna, Wołowiec Dariusz, Ziółkowska Ewelina, Robak Ewa & Korycka-Wołowiec Anna. (2012) Osoczowe stężenie cytokin limfo-i angiogennych u chorych na chłoniaka rozlanego z dużych komórek B. Acta Haematologica Polonica 43:3, pages 277-284.
Crossref
Crossref
Jonathan W. Friedberg. (2011) New Strategies in Diffuse Large B-cell Lymphoma: Translating Findings from Gene Expression Analyses into Clinical Practice. Clinical Cancer Research 17:19, pages 6112-6117.
Crossref
Crossref
Sandhya Girish, Steven W Martin, Mark C Peterson, Lei K. Zhang, Hong Zhao, Joseph Balthasar, Raymond Evers, Honghui Zhou, Min Zhu, Lewis Klunk, Chao Han, Eva Gil Berglund, Shiew-Mei Huang & Amita Joshi. (2011) AAPS Workshop Report: Strategies to Address Therapeutic Protein–Drug Interactions during Clinical Development. The AAPS Journal 13:3, pages 405-416.
Crossref
Crossref
Renée L Mulder, Elvira C van Dalen, Malon Van den Hof, Edith Leclercq, Dorine Bresters, Bart GP Koot, Sharon M Castellino, Yoon Loke, Piet N Post, Huib N Caron, Aleida Postma & Leontien CM Kremer. (2011) Hepatic late adverse effects after antineoplastic treatment for childhood cancer. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Eliza A. Hawkes, Alicia F.C. Okines, Chris Plummer & David Cunningham. (2011) Cardiotoxicity in Patients Treated With Bevacizumab Is Potentially Reversible. Journal of Clinical Oncology 29:18, pages e560-e562.
Crossref
Crossref
Tom van Meerten & Anton Hagenbeek. (2011) Novel antibodies against follicular non-Hodgkin’s lymphoma. Best Practice & Research Clinical Haematology 24:2, pages 231-256.
Crossref
Crossref
Honghui ZhouMary Ann Mascelli. (2011) Mechanisms of Monoclonal Antibody–Drug Interactions. Annual Review of Pharmacology and Toxicology 51:1, pages 359-372.
Crossref
Crossref
Mitchell R Smith. (2011) Should there be a standard therapy for mantle cell lymphoma?. Future Oncology 7:2, pages 227-237.
Crossref
Crossref
Sophie Dupire & Bertrand Coiffier. (2010) Targeted treatment and new agents in diffuse large B cell lymphoma. International Journal of Hematology 92:1, pages 12-24.
Crossref
Crossref
Semra Paydas. (2010) Anti-angiogenic strategies will be a revolution in lymphoma?. Leukemia Research 34:4, pages 552.
Crossref
Crossref
Dita Gratzinger, Ranjana Advani, Shuchun Zhao, Neha Talreja, Robert J. Tibshirani, Ragini Shyam, Sandra Horning, Laurie H. Sehn, Pedro Farinha, Javier Briones, Izidore S. Lossos, Randy D. Gascoyne & Yasodha Natkunam. (2010) Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP). British Journal of Haematology 148:2, pages 235-244.
Crossref
Crossref
Semra Paydas, Melek Ergin, Gulsah Seydaoglu, Seyda Erdogan & Sinan Yavuz. (2009) Pronostic significance of angiogenic/lymphangiogenic, anti-apoptotic, inflammatory and viral factors in 88 cases with diffuse large B cell lymphoma and review of the literature. Leukemia Research 33:12, pages 1627-1635.
Crossref
Crossref
Hélène Blasco, Etienne Chatelut, Isabelle Benz de Bretagne, Nicolas Congy-Jolivet & Chantal Le Guellec. (2009) Pharmacokinetics of rituximab associated with CHOP chemotherapy in B-cell non-Hodgkin lymphoma. Fundamental & Clinical Pharmacology 23:5, pages 601-608.
Crossref
Crossref
Stephen Ansell. 2009. Emerging Protein Biotherapeutics. Emerging Protein Biotherapeutics.
Sandrine Roulland & Bertrand Nadel. (2009) Du bon usage des profils d’expression génique pour la thérapeutique des lymphomes. médecine/sciences 25:6-7, pages 553-555.
Crossref
Crossref
S. Kassam & Silvia Montoto. (2009) New treatment options for the management of non-Hodgkin lymphoma. memo - Magazine of European Medical Oncology 2:2, pages 94-99.
Crossref
Crossref
Angelo Delmonte, Michele Ghielmini & Cristiana Sessa. (2009) Beyond Monoclonal Antibodies: New Therapeutic Agents in Non-Hodgkin’s Lymphomas. The Oncologist 14:5, pages 511-525.
Crossref
Crossref
J. Ruan, K. Hajjar, S. Rafii & J.P. Leonard. (2009) Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma. Annals of Oncology 20:3, pages 413-424.
Crossref
Crossref
G. Lenz, G. Wright, S.S. Dave, W. Xiao, J. Powell, H. Zhao, W. Xu, B. Tan, N. Goldschmidt, J. Iqbal, J. Vose, M. Bast, K. Fu, D.D. Weisenburger, T.C. Greiner, J.O. Armitage, A. Kyle, L. May, R.D. Gascoyne, J.M. Connors, G. Troen, H. Holte, S. Kvaloy, D. Dierickx, G. Verhoef, J. Delabie, E.B. Smeland, P. Jares, A. Martinez, A. Lopez-Guillermo, E. Montserrat, E. Campo, R.M. Braziel, T.P. Miller, L.M. Rimsza, J.R. Cook, B. Pohlman, J. Sweetenham, R.R. Tubbs, R.I. Fisher, E. Hartmann, A. Rosenwald, G. Ott, H.-K. Muller-Hermelink, D. Wrench, T.A. Lister, E.S. Jaffe, W.H. Wilson, W.C. Chan & L.M. Staudt. (2008) Stromal Gene Signatures in Large-B-Cell Lymphomas. New England Journal of Medicine 359:22, pages 2313-2323.
Crossref
Crossref
Sverker Hasselblom, Ulrika Hansson, Margret Sigurdardottir, Herman Nilsson-Ehle, Brje Ridell & Per-Ola Andersson. (2008) Expression of CD68 tumor-associated macrophages in patients with diffuse large B-cell lymphoma and its relation to prognosis. Pathology International 58:8, pages 529-532.
Crossref
Crossref
John P. Leonard, Peter Martin, Jacqueline Barrientos & Rebecca Elstrom. (2008) Targeted Treatment and New Agents in Diffuse Large B-Cell Lymphoma. Seminars in Hematology 45, pages S11-S16.
Crossref
Crossref
Mitchell R. Smith. (2008) Antibodies and Hematologic Malignancies. The Cancer Journal 14:3, pages 184-190.
Crossref
Crossref
Brad Kahl. (2008) Chemotherapy Combinations With Monoclonal Antibodies in Non-Hodgkin’s Lymphoma. Seminars in Hematology 45:2, pages 90-94.
Crossref
Crossref
Tara Seshadri, John Kuruvilla, Michael Crump & Armand Keating. (2008) Salvage Therapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma. Biology of Blood and Marrow Transplantation 14:3, pages 259-267.
Crossref
Crossref
Kristen N. Ganjoo, Annette M. Moore, Attilio Orazi, Joy A. Sen, Cynthia S. Johnson & Caroline S. An. (2007) The importance of angiogenesis markers in the outcome of patients with diffuse large B cell lymphoma: a retrospective study of 97 patients. Journal of Cancer Research and Clinical Oncology 134:3, pages 381-387.
Crossref
Crossref
Dita Gratzinger, Shuchun Zhao, Robert J Tibshirani, Eric D Hsi, Christine P Hans, Brad Pohlman, Martin Bast, Abraham Avigdor, Ginette Schiby, Arnon Nagler, Gerald E ByrneJrJr, Izidore S Lossos & Yasodha Natkunam. (2008) Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy. Laboratory Investigation 88:1, pages 38-47.
Crossref
Crossref
Delvys Rodriguez‐Abreu, Volmar Belisario Filho & Emanuele Zucca. (2007) Peripheral T‐cell lymphomas, unspecified (or not otherwise specified): a review. Hematological Oncology 26:1, pages 8-20.
Crossref
Crossref
Kathleen Seitz & Ghui Zhou. (2013) Pharmacokinetic Drug‐Drug Interaction Potentials for Therapeutic Monoclonal Antibodies: Reality Check. The Journal of Clinical Pharmacology 47:9, pages 1104-1118.
Crossref
Crossref
H F Fernandez, M P Escalón, D Pereira & H M Lazarus. (2007) Autotransplant conditioning regimens for aggressive lymphoma: are we on the right road?. Bone Marrow Transplantation 40:6, pages 505-513.
Crossref
Crossref
. (2007) Current Awareness in Hematological Oncology. Hematological Oncology 25:1, pages 44-51.
Crossref
Crossref
. (2006) Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiology and Drug Safety 16:1.
Crossref
Crossref
Jia Ruan, Elizabeth Hyjek, Pouneh Kermani, Paul J. Christos, Andrea T. Hooper, Morton Coleman, Barbara Hempstead, John P. Leonard, Amy Chadburn & Shahin Rafii. (2006) Magnitude of Stromal Hemangiogenesis Correlates with Histologic Subtype of Non–Hodgkin's Lymphoma. Clinical Cancer Research 12:19, pages 5622-5631.
Crossref
Crossref